[Management of malignant hyperthermia].
D000138:Acidosis / Q000150:complications; D058186:Acute Kidney Injury / Q000150:complications; D000768:Anesthesia, General / Q000009:adverse effects; D001145:Arrhythmias, Cardiac / Q000150:complications; D002128:Calcium Metabolism Disorders / Q000150:complications; D002462:Cell Membrane / Q000378:metabolism; D003402:Creatine Kinase / Q000097:blood; D003490:Cyanosis / Q000150:complications; D003655:Decerebrate State / Q000150:complications; D004211:Disseminated Intravascular Coagulation / Q000150:complications; D005334:Fever / Q000150:complications / Q000209:etiology / Q000235:genetics / Q000628:therapy*; D006333:Heart Failure / Q000150:complications; D006461:Hemolysis; D006801:Humans; D006943:Hyperglycemia / Q000150:complications; D009125:Muscle Relaxants, Central / Q000009:adverse effects; D009132:Muscles / Q000378:metabolism; D009206:Myocardium / Q000378:metabolism; D009212:Myoglobinuria / Q000150:complications
D009125:Muscle Relaxants, Central; D003402:Creatine Kinase
Zur Behandlung der malignen Hyperthermie.